JPRN-UMIN000005960招募中未知
ow-dose thalidomide treatment for patients with relapsed and refractory multiple myeloma. - Low-dose thalidomide treatment for patients with relapsed and refractory multiple myeloma.
Gunma Hematological Disease Study Group0 个研究点目标入组 70 人开始时间: 2011年7月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) patients with uncontrollable infection. (2)patients with psychological diseases. (3)female who can have children. (4)patients who the doctor think unsuitable for this study.
研究者
相似试验
进行中（未招募）
1 期
Efficacy of thalidomide in the treatment of heavy and frequent nose bleeding in patients affected by hereditary hemorrhagic telangiectasiaSevere recurrent epistaxis in hereditary hemorrhagic telangiectasiaMedDRA version: 14.1Level: LLTClassification code 10038554Term: Rendu-Osler-Weber syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-004096-36-ITOSPEDALE POLICLINICO S. MATTEO31
已完成
3 期
Effect of Thalidomide in Covid 19 pneumoniaPneumonia caused by Coronavirus 2019, COVID19.Coronavirus infection, unspecifiedB34.2IRCT20200428047232N1Esfahan University of Medical Sciences60
尚未招募
不适用
Addition of oral thalidomide to standard antitubercular regimen for initial 2 months improves the outcome in patients of tubercular meningitis as compared to standard therapy alone.CTRI/2020/08/027438AIIMS Bhubaneswar
已完成
不适用
Thalidomide for patients with severe autoimmune disease or autoinflammatory diseaseSevere autoimmune disease or autoinflammatory disease who was refractory against standard treatmentJPRN-UMIN000034534Department of Pediatrics, Yokohama City University Hospital5
招募中
不适用
Consolidation treatment of Lenalidomide for patients with adult T-cell leukemia/lymphoma ineligible for hematopoietic stem cell transplant.JPRN-UMIN000030095orth Japan Hematology Study Group15